Drugs / XZP-5610
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT04913090 | May 2021 → Mar 2022 | metabolic dysfunction-associated steatohepatitis | Xuanzhu Biopharmaceutical Co., Ltd. | Unknown | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | XZP-5610 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04913090 ↗ |
| Route | Oral | “Tablet(s) administered orally once daily for 1 Day” NCT04913090 ↗ |